Compare ONB & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONB | CYTK |
|---|---|---|
| Founded | 1834 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 10.7B |
| IPO Year | 2012 | 2004 |
| Metric | ONB | CYTK |
|---|---|---|
| Price | $25.88 | $76.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 19 |
| Target Price | $27.25 | ★ $89.26 |
| AVG Volume (30 Days) | ★ 3.9M | 1.8M |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.46% | N/A |
| EPS Growth | ★ 6.55 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $125,616,000.00 | $13,368,000.00 |
| Revenue This Year | $27.93 | $7.37 |
| Revenue Next Year | $5.10 | $310.19 |
| P/E Ratio | $43.92 | ★ N/A |
| Revenue Growth | ★ 6.07 | N/A |
| 52 Week Low | $19.39 | $35.22 |
| 52 Week High | $27.36 | $88.31 |
| Indicator | ONB | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 40.89 | 47.22 |
| Support Level | $25.55 | $73.95 |
| Resistance Level | $26.17 | $79.66 |
| Average True Range (ATR) | 0.44 | 2.72 |
| MACD | -0.15 | -0.06 |
| Stochastic Oscillator | 11.52 | 45.62 |
Old National Bancorp is a provider of lending and deposit services. The bank offers comprehensive wealth management, trust, investment advisory, brokerage, and foreign currency services. For businesses, it provides treasury management, merchant, and capital markets services as well as community development lending and equity investment solutions intended to produce jobs and revitalize its communities. It earns interest income on loans as well as fee income from the origination of loans and from providing other services to its clients.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.